ID   GLTP_HUMAN              Reviewed;         209 AA.
AC   Q9NZD2; Q53Z13; Q96J68;
DT   27-MAR-2002, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   10-MAY-2017, entry version 137.
DE   RecName: Full=Glycolipid transfer protein;
DE            Short=GLTP;
GN   Name=GLTP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Skin fibroblast;
RX   PubMed=15287756; DOI=10.1021/bi0495432;
RA   Li X.-M., Malakhova M.L., Lin X., Pike H.M., Chung T.,
RA   Molotkovsky J.G., Brown R.E.;
RT   "Human glycolipid transfer protein: probing conformation using
RT   fluorescence spectroscopy.";
RL   Biochemistry 43:10285-10294(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND TISSUE SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=18261224; DOI=10.1186/1471-2164-9-72;
RA   Zou X., Chung T., Lin X., Malakhova M.L., Pike H.M., Brown R.E.;
RT   "Human glycolipid transfer protein (GLTP) genes: organization,
RT   transcriptional status and evolution.";
RL   BMC Genomics 9:72-72(2008).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Caudate nucleus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   FUNCTION.
RX   PubMed=15504043; DOI=10.1021/bi0492197;
RA   Rao C.S., Lin X., Pike H.M., Molotkovsky J.G., Brown R.E.;
RT   "Glycolipid transfer protein mediated transfer of glycosphingolipids
RT   between membranes: a model for action based on kinetic and
RT   thermodynamic analyses.";
RL   Biochemistry 43:13805-13815(2004).
RN   [7]
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=17980653; DOI=10.1016/j.bbalip.2007.09.001;
RA   Tuuf J., Mattjus P.;
RT   "Human glycolipid transfer protein -- intracellular localization and
RT   effects on the sphingolipid synthesis.";
RL   Biochim. Biophys. Acta 1771:1353-1363(2007).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF APOPROTEIN AND IN COMPLEX
RP   WITH GLYCOLIPID, FUNCTION, AND MUTAGENESIS OF ILE-45; ASP-48; ASN-52;
RP   LYS-55; TRP-96; PHE-103; LEU-136; HIS-140; PHE-148; LEU-165; PHE-183
RP   AND TYR-207.
RX   PubMed=15329726; DOI=10.1038/nature02856;
RA   Malinina L., Malakhova M.L., Teplov A., Brown R.E., Patel D.J.;
RT   "Structural basis for glycosphingolipid transfer specificity.";
RL   Nature 430:1048-1053(2004).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) IN COMPLEXES WITH
RP   GLYCOSPHINGOLIPIDS, AND SUBUNIT.
RX   PubMed=17105344; DOI=10.1371/journal.pbio.0040362;
RA   Malinina L., Malakhova M.L., Kanack A.T., Lu M., Abagyan R.,
RA   Brown R.E., Patel D.J.;
RT   "The liganding of glycolipid transfer protein is controlled by
RT   glycolipid acyl structure.";
RL   PLoS Biol. 4:1996-2011(2006).
CC   -!- FUNCTION: Accelerates the intermembrane transfer of various
CC       glycolipids. Catalyzes the transfer of various glycosphingolipids
CC       between membranes but does not catalyze the transfer of
CC       phospholipids. May be involved in the intracellular translocation
CC       of glucosylceramides. {ECO:0000269|PubMed:15329726,
CC       ECO:0000269|PubMed:15504043, ECO:0000269|PubMed:17980653,
CC       ECO:0000269|PubMed:18261224}.
CC   -!- SUBUNIT: Monomer. {ECO:0000269|PubMed:15329726,
CC       ECO:0000269|PubMed:17105344}.
CC   -!- INTERACTION:
CC       Q96DZ9:CMTM5; NbExp=3; IntAct=EBI-2859814, EBI-2548702;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17980653}.
CC   -!- TISSUE SPECIFICITY: Detected in fibroblasts (at protein level).
CC       Detected in fibroblasts and in various cancer cell lines.
CC       {ECO:0000269|PubMed:17980653, ECO:0000269|PubMed:18261224}.
CC   -!- SIMILARITY: Belongs to the GLTP family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF209704; AAF33210.1; -; mRNA.
DR   EMBL; AY372530; AAR85984.1; -; mRNA.
DR   EMBL; AY372531; AAR85985.1; -; mRNA.
DR   EMBL; AY372532; AAR87373.1; -; mRNA.
DR   EMBL; AK313457; BAG36244.1; -; mRNA.
DR   EMBL; CH471054; EAW97880.1; -; Genomic_DNA.
DR   EMBL; BC009932; AAH09932.1; -; mRNA.
DR   CCDS; CCDS9136.1; -.
DR   RefSeq; NP_057517.1; NM_016433.3.
DR   UniGene; Hs.381256; -.
DR   PDB; 1SWX; X-ray; 1.65 A; A=1-209.
DR   PDB; 1SX6; X-ray; 1.95 A; A=1-209.
DR   PDB; 2EUK; X-ray; 1.85 A; A=1-209.
DR   PDB; 2EUM; X-ray; 2.30 A; A=1-209.
DR   PDB; 2EVD; X-ray; 2.00 A; A=1-209.
DR   PDB; 2EVL; X-ray; 2.20 A; A=1-209.
DR   PDB; 2EVS; X-ray; 2.20 A; A/E=1-209.
DR   PDB; 2EVT; X-ray; 1.99 A; A=1-209.
DR   PDB; 3RIC; X-ray; 2.10 A; A=1-209.
DR   PDB; 3RWV; X-ray; 1.50 A; A/B=1-209.
DR   PDB; 3RZN; X-ray; 1.10 A; A=1-209.
DR   PDB; 3S0I; X-ray; 1.50 A; A=1-209.
DR   PDB; 3S0K; X-ray; 1.40 A; A=1-209.
DR   PDB; 4GH0; X-ray; 1.35 A; A=1-209.
DR   PDB; 4GHP; X-ray; 1.90 A; A=1-209.
DR   PDB; 4GHS; X-ray; 3.20 A; A/B=1-209.
DR   PDB; 4GIX; X-ray; 1.80 A; A=1-209.
DR   PDB; 4GJQ; X-ray; 2.00 A; A/B=1-209.
DR   PDB; 4GVT; X-ray; 2.90 A; A=1-209.
DR   PDB; 4GXD; X-ray; 2.10 A; A=1-209.
DR   PDB; 4GXG; X-ray; 2.40 A; A/B/D/E=1-209.
DR   PDB; 4H2Z; X-ray; 1.45 A; A=1-209.
DR   PDBsum; 1SWX; -.
DR   PDBsum; 1SX6; -.
DR   PDBsum; 2EUK; -.
DR   PDBsum; 2EUM; -.
DR   PDBsum; 2EVD; -.
DR   PDBsum; 2EVL; -.
DR   PDBsum; 2EVS; -.
DR   PDBsum; 2EVT; -.
DR   PDBsum; 3RIC; -.
DR   PDBsum; 3RWV; -.
DR   PDBsum; 3RZN; -.
DR   PDBsum; 3S0I; -.
DR   PDBsum; 3S0K; -.
DR   PDBsum; 4GH0; -.
DR   PDBsum; 4GHP; -.
DR   PDBsum; 4GHS; -.
DR   PDBsum; 4GIX; -.
DR   PDBsum; 4GJQ; -.
DR   PDBsum; 4GVT; -.
DR   PDBsum; 4GXD; -.
DR   PDBsum; 4GXG; -.
DR   PDBsum; 4H2Z; -.
DR   ProteinModelPortal; Q9NZD2; -.
DR   SMR; Q9NZD2; -.
DR   BioGrid; 119392; 6.
DR   DIP; DIP-59418N; -.
DR   IntAct; Q9NZD2; 2.
DR   STRING; 9606.ENSP00000315263; -.
DR   DrugBank; DB03600; Decanoic Acid.
DR   DrugBank; DB04465; Lactose.
DR   DrugBank; DB03017; Lauric Acid.
DR   DrugBank; DB04224; Oleic Acid.
DR   DrugBank; DB03203; Sphingosine.
DR   iPTMnet; Q9NZD2; -.
DR   PhosphoSitePlus; Q9NZD2; -.
DR   BioMuta; GLTP; -.
DR   DMDM; 20138399; -.
DR   EPD; Q9NZD2; -.
DR   MaxQB; Q9NZD2; -.
DR   PaxDb; Q9NZD2; -.
DR   PeptideAtlas; Q9NZD2; -.
DR   PRIDE; Q9NZD2; -.
DR   DNASU; 51228; -.
DR   Ensembl; ENST00000318348; ENSP00000315263; ENSG00000139433.
DR   GeneID; 51228; -.
DR   KEGG; hsa:51228; -.
DR   UCSC; uc001tpm.3; human.
DR   CTD; 51228; -.
DR   GeneCards; GLTP; -.
DR   HGNC; HGNC:24867; GLTP.
DR   HPA; HPA056461; -.
DR   MIM; 608949; gene.
DR   neXtProt; NX_Q9NZD2; -.
DR   OpenTargets; ENSG00000139433; -.
DR   PharmGKB; PA142671729; -.
DR   eggNOG; KOG3221; Eukaryota.
DR   eggNOG; ENOG410YFEA; LUCA.
DR   GeneTree; ENSGT00800000124166; -.
DR   HOGENOM; HOG000199421; -.
DR   HOVERGEN; HBG019001; -.
DR   InParanoid; Q9NZD2; -.
DR   OMA; RGLEFTC; -.
DR   OrthoDB; EOG091G0IIT; -.
DR   PhylomeDB; Q9NZD2; -.
DR   TreeFam; TF317467; -.
DR   Reactome; R-HSA-1660662; Glycosphingolipid metabolism.
DR   ChiTaRS; GLTP; human.
DR   EvolutionaryTrace; Q9NZD2; -.
DR   GeneWiki; GLTP; -.
DR   GenomeRNAi; 51228; -.
DR   PRO; PR:Q9NZD2; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Bgee; ENSG00000139433; -.
DR   CleanEx; HS_GLTP; -.
DR   ExpressionAtlas; Q9NZD2; baseline and differential.
DR   Genevisible; Q9NZD2; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IC:HGNC.
DR   GO; GO:0051861; F:glycolipid binding; IDA:HGNC.
DR   GO; GO:0017089; F:glycolipid transporter activity; IDA:HGNC.
DR   GO; GO:0008289; F:lipid binding; IDA:HGNC.
DR   GO; GO:0046836; P:glycolipid transport; IDA:HGNC.
DR   GO; GO:0006687; P:glycosphingolipid metabolic process; TAS:Reactome.
DR   InterPro; IPR014830; Glycolipid_transfer_prot_dom.
DR   Pfam; PF08718; GLTP; 1.
DR   SUPFAM; SSF110004; SSF110004; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Complete proteome; Cytoplasm;
KW   Lipid transport; Reference proteome; Repeat; Transport.
FT   INIT_MET      1      1       Removed. {ECO:0000250|UniProtKB:P68266}.
FT   CHAIN         2    209       Glycolipid transfer protein.
FT                                /FTId=PRO_0000148915.
FT   REPEAT       45     55       1.
FT   REPEAT       56     66       2.
FT   REGION       45     66       2 X 12 AA approximate tandem repeats.
FT   REGION       48     55       Glycolipid binding.
FT   BINDING     140    140       Glycolipid.
FT                                {ECO:0000269|PubMed:15329726}.
FT   BINDING     207    207       Glycolipid.
FT                                {ECO:0000269|PubMed:15329726}.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000250|UniProtKB:P68266}.
FT   MUTAGEN      45     45       I->N: 18% decrease in activity.
FT                                {ECO:0000269|PubMed:15329726}.
FT   MUTAGEN      48     48       D->V: Significant inactivation; 15%
FT                                residual activity.
FT                                {ECO:0000269|PubMed:15329726}.
FT   MUTAGEN      52     52       N->I: Significant inactivation; 15%
FT                                residual activity.
FT                                {ECO:0000269|PubMed:15329726}.
FT   MUTAGEN      55     55       K->I: No loss of activity; 90-97%
FT                                residual activity.
FT                                {ECO:0000269|PubMed:15329726}.
FT   MUTAGEN      96     96       W->A: Almost complete inactivation; 1-3%
FT                                residual activity.
FT                                {ECO:0000269|PubMed:15329726}.
FT   MUTAGEN      96     96       W->F: Partial inactivation; 63% residual
FT                                activity. {ECO:0000269|PubMed:15329726}.
FT   MUTAGEN     103    103       F->S: About 25% decrease in activity.
FT                                {ECO:0000269|PubMed:15329726}.
FT   MUTAGEN     136    136       L->R: Significant inactivation; 5%
FT                                residual activity.
FT                                {ECO:0000269|PubMed:15329726}.
FT   MUTAGEN     140    140       H->L: Almost complete inactivation; 1-3%
FT                                residual activity.
FT                                {ECO:0000269|PubMed:15329726}.
FT   MUTAGEN     148    148       F->S: About 50% decrease in activity.
FT                                {ECO:0000269|PubMed:15329726}.
FT   MUTAGEN     165    165       L->R: 46% decrease in activity.
FT                                {ECO:0000269|PubMed:15329726}.
FT   MUTAGEN     183    183       F->S: No loss of activity; 90% residual
FT                                activity. {ECO:0000269|PubMed:15329726}.
FT   MUTAGEN     207    207       Y->L: No loss of activity; 90-97%
FT                                residual activity.
FT                                {ECO:0000269|PubMed:15329726}.
FT   HELIX         4      6       {ECO:0000244|PDB:4GIX}.
FT   HELIX        20     27       {ECO:0000244|PDB:3RZN}.
FT   TURN         28     30       {ECO:0000244|PDB:3RIC}.
FT   HELIX        31     36       {ECO:0000244|PDB:3RZN}.
FT   HELIX        40     42       {ECO:0000244|PDB:3RZN}.
FT   HELIX        43     62       {ECO:0000244|PDB:3RZN}.
FT   TURN         64     67       {ECO:0000244|PDB:3RZN}.
FT   HELIX        70     81       {ECO:0000244|PDB:3RZN}.
FT   HELIX        82     84       {ECO:0000244|PDB:3RZN}.
FT   HELIX        89    112       {ECO:0000244|PDB:3RZN}.
FT   STRAND      118    120       {ECO:0000244|PDB:1SX6}.
FT   HELIX       125    135       {ECO:0000244|PDB:3RZN}.
FT   HELIX       137    139       {ECO:0000244|PDB:3RZN}.
FT   HELIX       142    151       {ECO:0000244|PDB:3RZN}.
FT   HELIX       152    154       {ECO:0000244|PDB:3RZN}.
FT   HELIX       158    165       {ECO:0000244|PDB:3RZN}.
FT   TURN        166    168       {ECO:0000244|PDB:3RZN}.
FT   HELIX       173    200       {ECO:0000244|PDB:3RZN}.
SQ   SEQUENCE   209 AA;  23850 MW;  F3DD96D702AE22CF CRC64;
     MALLAEHLLK PLPADKQIET GPFLEAVSHL PPFFDCLGSP VFTPIKADIS GNITKIKAVY
     DTNPAKFRTL QNILEVEKEM YGAEWPKVGA TLALMWLKRG LRFIQVFLQS ICDGERDENH
     PNLIRVNATK AYEMALKKYH GWIVQKIFQA ALYAAPYKSD FLKALSKGQN VTEEECLEKI
     RLFLVNYTAT IDVIYEMYTQ MNAELNYKV
//
